Tags |
|
|
Links |
|
|
Advice You - Medical Billing - GX1 Record
If you thought it was safe to come out of your bunker now that our review of the GX0 record is over, you may want to crawl back in. We're not quite
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
done with our oxygen billing review in regard to medical billing in general. In this installment we begin our review of the narrative record, which
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
s the GX1 record.
The GX1 record has only 7 fields in it. You would therefore think that there is just no way to screw this record up. And yet, th
The GX1 record has only 7 fields in it. You would therefore think that there is just no way to screw this record up. And yet, th
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
re are more problems with the GX1 record and denials than the GX0 record. The reason for this is because the majority of the fields are not simple o
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
e or two character replies. Most of the responses are narrative ones and lengthy at that. When you combine that with the fact that, unfortunately,
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
any billers do not have English as their first language, this causes a number of problems. Proper training in narrative explanation is critical to g
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
tting these claims accepted by the carrier.
GX1 field 1, positions 1 - 3, is the record type. This field tells the carrier what the record is that
GX1 field 1, positions 1 - 3, is the record type. This field tells the carrier what the record is that
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
s being transmitted and needs to be filled with GX1 or the claim will be denied.
GX1 field 2, positions 4 - 5, is the sequence number. Because ther
GX1 field 2, positions 4 - 5, is the sequence number. Because ther
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
can be as many as 99 narrative records sent with each claim, a sequence number must be transmitted for each GX1 record. These are transmitted as GX
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
-01, GX1-02 and so on. These cannot be out of sequence or the claim will be denied. Also, the GX1 records must follow the GX0 records.
GX1 field 3
GX1 field 3
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
positions 6 - 22, is the patient control number. This is the same patient ID number that is transmitted in the CA0 record and all subsequent record
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
containing patient information. This number must match the CA0 record or the claim will be denied.
GX1 field 4, positions 23 - 112, is the test re
GX1 field 4, positions 23 - 112, is the test re
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
ults narrative. This field tells the carrier if the oxygen tests that were performed were done under unusual conditions. This can cover just about
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
nything from where the tests were performed to how they were performed. Also, an explanation of how these tests were interpreted is also required he
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
e if out of the ordinary.
GX1 field 5, positions 113 - 202, is additional medical findings. This is another narrative field where the carrier is to
GX1 field 5, positions 113 - 202, is additional medical findings. This is another narrative field where the carrier is to
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
d any additional medical findings to justify putting the patient on oxygen. This is required because oxygen use is very regulated and the carrier ne
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
ds to make absolutely sure that the patient is indeed in need of oxygen therapy. This is especially necessary if the PO2 levels are 60 mm Hg or abov
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
or oxygen saturation is above 90 percent. The reason is because in these cases, rarely is oxygen needed.
GX1 field 6, positions 203 - 292, is the
GX1 field 6, positions 203 - 292, is the
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
xercise routine narrative. This field tells the carrier any exercise that the patient has to do that required him to have a portable oxygen system.
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
GX1 field 7, positions 292 - 320, is filler national and must be filled with spaces.
This concludes our review of the GX1 record for medical billing
This concludes our review of the GX1 record for medical billing
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.adviceyou.org.ua/article/2042/adviceyou-Medical-Billing--GX1-Record.html">Medical Billing - GX1 Record</a>
BB link (for phorums):
[url=http://www.adviceyou.org.ua/article/2042/adviceyou-Medical-Billing--GX1-Record.html]Medical Billing - GX1 Record[/url]
Related Articles:
Principles Of Lean Manufacturing
Joint Vision In A Partnership Company
Bookmark it:
|